nach oben

Erschienen in:

28.04.2017 | Original Article

Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography

verfasst von: B . Puccini, L. Nassi, C. Minoia, S. Volpetti, R. Ciancia, P. C. Riccomagno, A. Di Rocco, A. Mulè, C. Toldo, M. C. Sassone, R. Guariglia, C. Filì, E. Finolezzi, S. Falorio, S. Zanon, A. Furlan, G. Doa, F. Zaja, on behalf of the Fondazione Italiana Linfomi Postgraduate Master course

Erschienen in: Annals of Hematology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Several studies suggested that staging bone marrow biopsy (BMB) could be omitted in patients with classical Hodgkin’s lymphoma (cHL) when a positron emission tomography/computed tomography (PET/CT) is performed at baseline.

To address the concordance between BMB and PET/CT in the detection of bone marrow involvement (BMI) and the BMB role in determining the Ann Arbor stage, we retrospectively collected data on 1244 consecutive patients with cHL diagnosed from January 2007 to December 2013. One thousand eighty-five patients who had undergone both BMB and PET/CT were analyzed, comparing the Ann Arbor stage assessed with PET/CT only to that resulting from PET/CT combined with BMB.

One hundred sixty-nine patients (16%) showed at least one focal skeletal lesion (FSL) at PET/CT evaluation. Only 55 patients had a positive BMB (5.1%); 34 of them presented at least one FSL at PET/CT. To the contrary, 895 out of 1030 patients with a negative BMB did not show any FSL (86.9%). Positive and negative predictive values of PET/CT for BMI were 20 and 98%, respectively; sensitivity and specificity were 62 and 87%, respectively. Fifty-four out of 55 patients with a positive BMB could have been evaluated as an advanced stage just after PET/CT; only one patient (0.1%) would have been differently treated without BMB.

Our data showed a very high negative predictive value of PET/CT for BMI and a negligible influence of BMB on treatment planning, strengthening the recent indications that BMB could be safely omitted in cHL patients staged with PET/CT.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtypes in the United States, 1992-2001. Blood 107:265–276CrossRefPubMedPubMedCentral

Stein H (2001) WHO histological classification of Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 237–253

Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861PubMed

Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636CrossRefPubMed

Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, Siakantaris MP, Korkolopoulou P, Kyrtsonis MC, Kokoris SI, Dimopoulou MN, Variamis E, Viniou NA, Konstantopoulos K, Dimitriadou EM, Androulaki A, Patsouris E, Doussis-Anagnostopoulou IA, Panayiotidis P, Boussiotis VA, Kittas C, Pangalis GA (2005) Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 105:1875–1880CrossRefPubMed

Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito F, Gavarotti P, Guglielmelli T, Orsucci L, Raviolo E, Rota Scalabrini D, Salvi F, Tonso A, Aglietta M, Boccadoro M, Gallamini A, Saglio G, Scassa E, Gallo E (2004) A large scale of bone marrow involvement in patients with Hodgkin’s lymphoma. Clin Lymphoma 5:50–55CrossRefPubMed

Connors JM (2005) State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 23:6400–6408CrossRefPubMed

Engert A, Eichenauer DA, Dreyling M (2010) Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v168–v171CrossRefPubMed

Zhang QY, Foucar K (2009) Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. Hematol Oncol Clin North Am 23:873–902CrossRefPubMed

10.

Bain BJ (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 26:315–318CrossRefPubMed

11.

Brunetti GA, Tendas A, Meloni E, Mancini D, Maggiore P, Scaramucci L, Giovannini M, Niscola P, Cartoni C, Alimena G (2011) Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol 90:1233–1235CrossRefPubMed

12.

Hjortholm N, Jaddini E, Halaburda K, Snarski E (2013) Strategies of pain reduction during the bone marrow biopsy. Ann Hematol 92:145–149CrossRefPubMed

13.

Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D’Amore F, Boesen AM, Roemer L, Specht L (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91:482–489PubMed

14.

Juweid ME, Strobaants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578CrossRefPubMed

15.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of Deauville five-point scale. Haematologica 99:1107–1113CrossRefPubMedPubMedCentral

16.

Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25–30CrossRefPubMed

17.

Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, Timothy AR (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340–3346PubMed

18.

Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN (1998) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609CrossRefPubMed

19.

Moulin-Romsee G, Hindié E, Cuenca X, Brice P, Decaudin D, Bénamor M, Brière J, Anitei M, Filmont JE, Sibon D, de Kerviler E, Moretti JL (2010) (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37:1095–1105CrossRefPubMed

20.

Pakos EE, Fotopoulos AD, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963PubMed

21.

El-Galaly TC, D’Amore F, Mylam KJ, de Nully BP, Bøgsted M, Bukh A, Specht L, Loft A, Iyer V, Hjorthaug K, Nielsen AL, Christiansen I, Madsen C, Johnsen HE, Hutchings M (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30:4508–4514CrossRefPubMed

22.

Cortés-Romera M, Sabaté-Llobera A, Mercadal-Vilchez S, Climent-Esteller F, Serrano-Maestro A, Gámez-Cenzano C, González-Barca E (2014) Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy. Clin Nucl Med 39:e46–e52CrossRefPubMed

23.

Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G (2008) FDG-PET in the detection of bone marrow disease in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 52:9–16PubMed

24.

Muzahir S, Mian M, Munir I, Nawaz MK, Faruqui ZS, Mufti KA, Bashir H, Uddin N, Siddiqui N, Maaz AU, Mahmood MT (2012) Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin’s lymphoma. Br J Radiol 85:e490–e496CrossRefPubMedPubMedCentral

25.

Pelosi E, Penna D, Douroukas A, Bellò M, Amati A, Arena V, Passera R, Bisi G (2011) Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 55:469–475PubMed

26.

Mittal BR, Manohar K, Malhotra P, Das R, Kashyap R, Bhattacharya A, Varma N, Varma S (2011) Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? Leuk Lymphoma 52:2111–2116CrossRefPubMed

27.

Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 38:1469–1476CrossRefPubMed

28.

Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, Nievelstein RA (2014) Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 25:921–927CrossRefPubMed

29.

Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin’s Lymphoma Study Group (2003) Involved field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma study group. J Clin Oncol 21:3601–3108CrossRefPubMed

30.

Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514CrossRefPubMed

31.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMed

32.

Weiler-Sagie M, Kagna O, Dann EJ, Ben-Barak A, Israel O (2014) Characterizing bone marrow involvement in Hodgkin’s lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging 41:1133–1140CrossRefPubMed

33.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068CrossRefPubMedPubMedCentral

34.

Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, Ladetto M (2014) Hodgkin’s lymphoma: ESMO clinical practice guidelines guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii70–iii75CrossRefPubMed

Titel: Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography
verfasst von: B . Puccini
L. Nassi
C. Minoia
S. Volpetti
R. Ciancia
P. C. Riccomagno
A. Di Rocco
A. Mulè
C. Toldo
M. C. Sassone
R. Guariglia
C. Filì
E. Finolezzi
S. Falorio
S. Zanon
A. Furlan
G. Doa
F. Zaja
on behalf of the Fondazione Italiana Linfomi Postgraduate Master course
Publikationsdatum: 28.04.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 7/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-2996-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Pyogenic brain abscesses treated with antibiotics in a patient with hemophagocytic lymphohistiocytosis on HLH-94 protocol

A Japanese infant with systemic juvenile xanthogranuloma mimicking severe microangiopathy

HbQ-India (HBA1:c.193G>C): hematological profiles and unique CE-HPLC findings of potential diagnostic utility in 65 cases

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin